Private company

ObsEva SA

Pharmaceutical preparations company1

In its 2023 annual report the company says: “We are a biopharmaceutical company focused on the development of novel therapies to improve women’s reproductive health. We are advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. We currently have worldwide, exclusive, commercial rights for nolasiban, except for the People’s Republic of China, where it has been sub-licensed to Yuyuan BioScience in January 2020.”25

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersV81
  • Incorporated inSwitzerland2
  • Business addressChemin Des Aulx, 12, Plan-Les-Ouates, V8 12282
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-79.8%Operating margin3
-152.2%Net margin3
-11.5%Revenue growth, 20223
-352.2%Return on equity3
0.33×Debt to equity3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development55¢$10.7M
  • Other costs45¢$8.9M
  • Income tax0¢$11.0K

Out of $19.6M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$19.6M in 2022
0$10.0M$20.0M$30.0M2017: $0$020172018: $0$020182019: $0$020192020: $0$020202021: $22.2M$22.2M20212022: $19.6M$19.6M2022−12%
Operating income56783-$15.7M in 2022−48% since 2016
-$150.0M-$100.0M-$50.0M02016: -$30.1M-$30.1M20162017: -$67.5M-$67.5M2017+124%2018: -$77.2M-$77.2M2018+14%2019: -$107.1M-$107.1M2019+39%2020: -$79.7M-$79.7M2020−26%2021: -$56.6M-$56.6M2021−29%2022: -$15.7M-$15.7M2022−72%
Net income56783-$29.9M in 2022−1% since 2016
-$150.0M-$100.0M-$50.0M02016: -$30.2M-$30.2M20162017: -$66.9M-$66.9M2017+122%2018: -$76.7M-$76.7M2018+15%2019: -$108.8M-$108.8M2019+42%2020: -$83.0M-$83.0M2020−24%2021: -$53.0M-$53.0M2021−36%2022: -$29.9M-$29.9M2022−44%
Fiscal year2016201720182019202020212022
Revenue$04$05$06$07$22.2M3$19.6M3
Research and development$53.9M3$10.7M3
Selling, general and admin$21.5M8
Operating income-$30.1M5-$67.5M6-$77.2M7-$107.1M8-$79.7M8-$56.6M3-$15.7M3
Interest$3.2M8
Income before tax-$52.8M3-$29.9M3
Income tax$213.0K3$11.0K3
Net income-$30.2M5-$66.9M6-$76.7M7-$108.8M8-$83.0M8-$53.0M3-$29.9M3
Earnings per share-$1.405-$2.256-$1.917-$2.497-$1.677-$0.703-$0.323
Earnings per share (diluted)-$1.405-$2.256-$1.917-$2.497-$1.677-$0.703-$0.323
Shares (weighted, basic)75.3M shares392.1M shares3
Shares (weighted, diluted)75.3M shares392.1M shares3

Compare ObsEva SA with another company

Corporate structure

ObsEva SA sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ObsEva SA

  • Ernest Loumaye Filed SC 13D on ObsEva SA, latest Apr 17, 2023 (3 filings since Feb 14, 2022)
  • Sofinnova Venture Partners VIII, L.P. Filed SC 13D/A on ObsEva SA, latest Feb 6, 2023 (2 filings since Feb 28, 2022)
  • ObsEva SA V8

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ObsEva SA reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$58.0K8 Dec 31, 2021$151.0K8 Dec 31, 2020−61.6%
Operating-lease assets (leased space)$227.0K3 Dec 31, 2022$774.0K3 Dec 31, 2021−70.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.4M3 Dec 31, 2022$54.7M3 Dec 31, 2021−84.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$24.5M8 Dec 31, 2021$26.6M8 Dec 31, 2020−7.9%

Leadership

Who has led ObsEva SA, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Brian O'Callaghan2023
2025
Board members and other officers (7)

Timeline

  1. Apr 11, 20238-K Entered a material agreement; Unregistered sale of shares16
  2. Mar 22, 20238-K Other events17
  3. Mar 15, 20238-K Listing notice or transfer; Regulation FD disclosure18
  4. Mar 13, 20238-K Executive or director change; Regulation FD disclosure19
  5. Mar 1, 20238-K Entered a material agreement; Unregistered sale of shares20
  6. Feb 24, 20238-K Entered a material agreement; Ended a material agreement; Exit or restructuring costs21
  7. Jan 3, 2023New chief executive Brian O'Callaghan becomes CEO9
  8. Jan 3, 20238-K Regulation FD disclosure22

Filings

102 filings to the SEC since October 2021: 2 annual reports, 7 major events, 12 insider forms, 5 large holders, 76 other. The latest 20:

  1. Apr 26, 202315-12G EDGAR
  2. Apr 17, 2023SC 13D EDGAR
  3. Apr 11, 20234 FORM 4 SUBMISSION EDGAR
  4. Apr 11, 20238-K EDGAR
  5. Mar 31, 202310-K EDGAR
  6. Mar 29, 2023EFFECT EDGAR
  7. Mar 29, 2023EFFECT EDGAR
  8. Mar 29, 2023EFFECT EDGAR
  9. Mar 29, 2023EFFECT EDGAR
  10. Mar 29, 2023EFFECT EDGAR
  11. Mar 29, 2023EFFECT EDGAR
  12. Mar 29, 2023EFFECT EDGAR
  13. Mar 28, 2023POS AM EDGAR
  14. Mar 28, 2023POS AM EDGAR
  15. Mar 28, 2023POS AM EDGAR
  16. Mar 28, 2023POS AM EDGAR
  17. Mar 28, 2023POS AM EDGAR
  18. Mar 28, 2023POS AM EDGAR
  19. Mar 28, 2023POS AM EDGAR
  20. Mar 28, 2023S-8 POS EDGAR

The 102 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 6, 2023Loumaye ErnestDirectorBuy4,000,000$0.10$400.0KForm 4
Feb 28, 2023Loumaye ErnestDirectorBuy4,000,000$0.11$440.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How ObsEva SA is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARObsEva SA1
  • CIK0001685316
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inSwitzerland1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business addressChemin Des Aulx, 12, Plan-Les-Ouates, V8 12281
  • Phone0041-0-22-552-15581
  • Shares outstanding113,177,287 as of Mar 24, 20233
  • Public float$136.0M as of Jun 30, 20223
  • On EDGAR sinceOct 14, 20161
  • Filings273 in all: 6-K (116), SC 13G/A (17), EFFECT (16), CORRESP (12), UPLOAD (10), SC 13G (9), 3 (8), POS AM (8)1
    All 35 form types

    8-K (7), 20-F (6), 424B5 (6), 6-K/A (5), F-3 (5), SC 13D/A (5), F-1/A (4), S-8 (4), S-8 POS (4), 4 (3), F-3/A (3), SC 13D (3), 424B3 (2), 424B4 (2), 424B7 (2), CT ORDER (2), DRS/A (2), DRSLTR (2), F-1 (2), 10-K (1), 15-12G (1), 25 (1), 3/A (1), 8-A12B (1), CERTNAS (1), DRS (1), F-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Latest 8-K (8-K) Apr 11, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
    SEC EDGAROther events
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25